Fundz

Fundz Deep Dive

Everything you need to win Beren Therapeutics — in one platform.

Who to reach, what to say, and why now on Beren Therapeutics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Beren Therapeutics — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Beren Therapeutics raises $300M in a combined equity and debt financing round led by CEO Jason Camm, targeting commercial readiness for its lead asset.

PRIVATEJun 10, 2026•5 days ago

Amount Raised

$300 Million

Thousand OaksBiotechnologyHealth CareTherapeutics

Description

Beren Therapeutics, based in Thousand Oaks, California, raised $300M in a combined equity and debt financing round. The funds will support commercial readiness activities for its lead asset and expand diagnostic integration networks. The company has advanced its product for FDA Breakthrough Therapy Designation and is in the Priority Review track. The financing will also aid in building a long-term patient access and family support program.

Company Information

Company

Beren Therapeutics

Location

Thousand Oaks, California, United States

About

Beren Therapeutics is a developer of cyclodextrin-based cholesterol trafficking therapeutics, focused on addressing infantile-onset Niemann-Pick disease, type C. The company is advancing its lead asset, adrabetadex, which has been granted FDA Breakthrough Therapy Designation. Beren intends to accelerate its commercial readiness and expand its diagnostic integration networks. Additionally, the company is building a patient access and family support program.

Related People

Suggested for you
3 contacts

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

1 more contact · See plans

Predictive Intelligence
Strategic

ML-powered predictions for Beren Therapeutics's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching Beren Therapeutics? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demoChoose your plan